table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2023-2032)
1.4.2 East Asia Market States and Outlook (2023-2032)
1.4.3 Europe Market States and Outlook (2023-2032)
1.4.4 South Asia Market States and Outlook (2023-2032)
1.4.5 Southeast Asia Market States and Outlook (2023-2032)
1.4.6 Middle East Market States and Outlook (2023-2032)
1.4.7 Africa Market States and Outlook (2023-2032)
1.4.8 Oceania Market States and Outlook (2023-2032)
1.4.9 South America Market States and Outlook (2023-2032)
1.5 Global Human Vaccines Administered Orally Market Size Analysis from 2023 to 2032
1.5.1 Global Human Vaccines Administered Orally Market Size Analysis from 2023 to 2032 by Consumption Volume
1.5.2 Global Human Vaccines Administered Orally Market Size Analysis from 2023 to 2032 by Value
1.5.3 Global Human Vaccines Administered Orally Price Trends Analysis from 2023 to 2032
1.6 COVID-19 Outbreak: Human Vaccines Administered Orally Industry Impact
Chapter 2 Global Human Vaccines Administered Orally Competition by Types, Applications, and Top Regions and Countries
2.1 Global Human Vaccines Administered Orally (Volume and Value) by Type
2.1.1 Global Human Vaccines Administered Orally Consumption and Market Share by Type (2017-2022)
2.1.2 Global Human Vaccines Administered Orally Revenue and Market Share by Type (2017-2022)
2.2 Global Human Vaccines Administered Orally (Volume and Value) by Application
2.2.1 Global Human Vaccines Administered Orally Consumption and Market Share by Application (2017-2022)
2.2.2 Global Human Vaccines Administered Orally Revenue and Market Share by Application (2017-2022)
2.3 Global Human Vaccines Administered Orally (Volume and Value) by Regions
2.3.1 Global Human Vaccines Administered Orally Consumption and Market Share by Regions (2017-2022)
2.3.2 Global Human Vaccines Administered Orally Revenue and Market Share by Regions (2017-2022)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2017-2022 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2017-2022 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Human Vaccines Administered Orally Sales, Consumption, Export, Import by Regions (2017-2022)
4.1 Global Human Vaccines Administered Orally Consumption by Regions (2017-2022)
4.2 North America Human Vaccines Administered Orally Sales, Consumption, Export, Import (2017-2022)
4.3 East Asia Human Vaccines Administered Orally Sales, Consumption, Export, Import (2017-2022)
4.4 Europe Human Vaccines Administered Orally Sales, Consumption, Export, Import (2017-2022)
4.5 South Asia Human Vaccines Administered Orally Sales, Consumption, Export, Import (2017-2022)
4.6 Southeast Asia Human Vaccines Administered Orally Sales, Consumption, Export, Import (2017-2022)
4.7 Middle East Human Vaccines Administered Orally Sales, Consumption, Export, Import (2017-2022)
4.8 Africa Human Vaccines Administered Orally Sales, Consumption, Export, Import (2017-2022)
4.9 Oceania Human Vaccines Administered Orally Sales, Consumption, Export, Import (2017-2022)
4.10 South America Human Vaccines Administered Orally Sales, Consumption, Export, Import (2017-2022)
Chapter 5 North America Human Vaccines Administered Orally Market Analysis
5.1 North America Human Vaccines Administered Orally Consumption and Value Analysis
5.1.1 North America Human Vaccines Administered Orally Market Under COVID-19
5.2 North America Human Vaccines Administered Orally Consumption Volume by Types
5.3 North America Human Vaccines Administered Orally Consumption Structure by Application
5.4 North America Human Vaccines Administered Orally Consumption by Top Countries
5.4.1 United States Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
5.4.2 Canada Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
5.4.3 Mexico Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
Chapter 6 East Asia Human Vaccines Administered Orally Market Analysis
6.1 East Asia Human Vaccines Administered Orally Consumption and Value Analysis
6.1.1 East Asia Human Vaccines Administered Orally Market Under COVID-19
6.2 East Asia Human Vaccines Administered Orally Consumption Volume by Types
6.3 East Asia Human Vaccines Administered Orally Consumption Structure by Application
6.4 East Asia Human Vaccines Administered Orally Consumption by Top Countries
6.4.1 China Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
6.4.2 Japan Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
6.4.3 South Korea Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
Chapter 7 Europe Human Vaccines Administered Orally Market Analysis
7.1 Europe Human Vaccines Administered Orally Consumption and Value Analysis
7.1.1 Europe Human Vaccines Administered Orally Market Under COVID-19
7.2 Europe Human Vaccines Administered Orally Consumption Volume by Types
7.3 Europe Human Vaccines Administered Orally Consumption Structure by Application
7.4 Europe Human Vaccines Administered Orally Consumption by Top Countries
7.4.1 Germany Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
7.4.2 UK Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
7.4.3 France Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
7.4.4 Italy Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
7.4.5 Russia Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
7.4.6 Spain Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
7.4.7 Netherlands Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
7.4.8 Switzerland Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
7.4.9 Poland Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
Chapter 8 South Asia Human Vaccines Administered Orally Market Analysis
8.1 South Asia Human Vaccines Administered Orally Consumption and Value Analysis
8.1.1 South Asia Human Vaccines Administered Orally Market Under COVID-19
8.2 South Asia Human Vaccines Administered Orally Consumption Volume by Types
8.3 South Asia Human Vaccines Administered Orally Consumption Structure by Application
8.4 South Asia Human Vaccines Administered Orally Consumption by Top Countries
8.4.1 India Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
8.4.2 Pakistan Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
8.4.3 Bangladesh Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
Chapter 9 Southeast Asia Human Vaccines Administered Orally Market Analysis
9.1 Southeast Asia Human Vaccines Administered Orally Consumption and Value Analysis
9.1.1 Southeast Asia Human Vaccines Administered Orally Market Under COVID-19
9.2 Southeast Asia Human Vaccines Administered Orally Consumption Volume by Types
9.3 Southeast Asia Human Vaccines Administered Orally Consumption Structure by Application
9.4 Southeast Asia Human Vaccines Administered Orally Consumption by Top Countries
9.4.1 Indonesia Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
9.4.2 Thailand Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
9.4.3 Singapore Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
9.4.4 Malaysia Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
9.4.5 Philippines Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
9.4.6 Vietnam Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
9.4.7 Myanmar Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
Chapter 10 Middle East Human Vaccines Administered Orally Market Analysis
10.1 Middle East Human Vaccines Administered Orally Consumption and Value Analysis
10.1.1 Middle East Human Vaccines Administered Orally Market Under COVID-19
10.2 Middle East Human Vaccines Administered Orally Consumption Volume by Types
10.3 Middle East Human Vaccines Administered Orally Consumption Structure by Application
10.4 Middle East Human Vaccines Administered Orally Consumption by Top Countries
10.4.1 Turkey Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
10.4.2 Saudi Arabia Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
10.4.3 Iran Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
10.4.4 United Arab Emirates Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
10.4.5 Israel Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
10.4.6 Iraq Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
10.4.7 Qatar Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
10.4.8 Kuwait Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
10.4.9 Oman Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
Chapter 11 Africa Human Vaccines Administered Orally Market Analysis
11.1 Africa Human Vaccines Administered Orally Consumption and Value Analysis
11.1.1 Africa Human Vaccines Administered Orally Market Under COVID-19
11.2 Africa Human Vaccines Administered Orally Consumption Volume by Types
11.3 Africa Human Vaccines Administered Orally Consumption Structure by Application
11.4 Africa Human Vaccines Administered Orally Consumption by Top Countries
11.4.1 Nigeria Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
11.4.2 South Africa Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
11.4.3 Egypt Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
11.4.4 Algeria Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
11.4.5 Morocco Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
Chapter 12 Oceania Human Vaccines Administered Orally Market Analysis
12.1 Oceania Human Vaccines Administered Orally Consumption and Value Analysis
12.2 Oceania Human Vaccines Administered Orally Consumption Volume by Types
12.3 Oceania Human Vaccines Administered Orally Consumption Structure by Application
12.4 Oceania Human Vaccines Administered Orally Consumption by Top Countries
12.4.1 Australia Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
12.4.2 New Zealand Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
Chapter 13 South America Human Vaccines Administered Orally Market Analysis
13.1 South America Human Vaccines Administered Orally Consumption and Value Analysis
13.1.1 South America Human Vaccines Administered Orally Market Under COVID-19
13.2 South America Human Vaccines Administered Orally Consumption Volume by Types
13.3 South America Human Vaccines Administered Orally Consumption Structure by Application
13.4 South America Human Vaccines Administered Orally Consumption Volume by Major Countries
13.4.1 Brazil Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
13.4.2 Argentina Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
13.4.3 Columbia Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
13.4.4 Chile Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
13.4.5 Venezuela Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
13.4.6 Peru Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
13.4.7 Puerto Rico Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
13.4.8 Ecuador Human Vaccines Administered Orally Consumption Volume from 2017 to 2022
Chapter 14 Company Profiles and Key Figures in Human Vaccines Administered Orally Business
14.1 Merck
14.1.1 Merck Company Profile
14.1.2 Merck Human Vaccines Administered Orally Product Specification
14.1.3 Merck Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.2 GSK
14.2.1 GSK Company Profile
14.2.2 GSK Human Vaccines Administered Orally Product Specification
14.2.3 GSK Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.3 Sanofi
14.3.1 Sanofi Company Profile
14.3.2 Sanofi Human Vaccines Administered Orally Product Specification
14.3.3 Sanofi Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.4 Lanzhou Institute
14.4.1 Lanzhou Institute Company Profile
14.4.2 Lanzhou Institute Human Vaccines Administered Orally Product Specification
14.4.3 Lanzhou Institute Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.5 Serum Institute
14.5.1 Serum Institute Company Profile
14.5.2 Serum Institute Human Vaccines Administered Orally Product Specification
14.5.3 Serum Institute Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.6 Valneva
14.6.1 Valneva Company Profile
14.6.2 Valneva Human Vaccines Administered Orally Product Specification
14.6.3 Valneva Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.7 Shanghai United Cell
14.7.1 Shanghai United Cell Company Profile
14.7.2 Shanghai United Cell Human Vaccines Administered Orally Product Specification
14.7.3 Shanghai United Cell Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.8 Bibcol
14.8.1 Bibcol Company Profile
14.8.2 Bibcol Human Vaccines Administered Orally Product Specification
14.8.3 Bibcol Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.9 PaxVax
14.9.1 PaxVax Company Profile
14.9.2 PaxVax Human Vaccines Administered Orally Product Specification
14.9.3 PaxVax Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.10 Vabiotech
14.10.1 Vabiotech Company Profile
14.10.2 Vabiotech Human Vaccines Administered Orally Product Specification
14.10.3 Vabiotech Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.11 Tiantan Biological
14.11.1 Tiantan Biological Company Profile
14.11.2 Tiantan Biological Human Vaccines Administered Orally Product Specification
14.11.3 Tiantan Biological Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.12 EuBiologics
14.12.1 EuBiologics Company Profile
14.12.2 EuBiologics Human Vaccines Administered Orally Product Specification
14.12.3 EuBiologics Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.13 Panacea Biotec Ltd
14.13.1 Panacea Biotec Ltd Company Profile
14.13.2 Panacea Biotec Ltd Human Vaccines Administered Orally Product Specification
14.13.3 Panacea Biotec Ltd Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.14 Bio-Med
14.14.1 Bio-Med Company Profile
14.14.2 Bio-Med Human Vaccines Administered Orally Product Specification
14.14.3 Bio-Med Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.15 Halfkin Bio-Pharmaceuticals
14.15.1 Halfkin Bio-Pharmaceuticals Company Profile
14.15.2 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Product Specification
14.15.3 Halfkin Bio-Pharmaceuticals Human Vaccines Administered Orally Production Capacity, Revenue, Price and Gross Margin (2017-2022)
Chapter 15 Global Human Vaccines Administered Orally Market Forecast (2023-2032)
15.1 Global Human Vaccines Administered Orally Consumption Volume, Revenue and Price Forecast (2023-2032)
15.1.1 Global Human Vaccines Administered Orally Consumption Volume and Growth Rate Forecast (2023-2032)
15.1.2 Global Human Vaccines Administered Orally Value and Growth Rate Forecast (2023-2032)
15.2 Global Human Vaccines Administered Orally Consumption Volume, Value and Growth Rate Forecast by Region (2023-2032)
15.2.1 Global Human Vaccines Administered Orally Consumption Volume and Growth Rate Forecast by Regions (2023-2032)
15.2.2 Global Human Vaccines Administered Orally Value and Growth Rate Forecast by Regions (2023-2032)
15.2.3 North America Human Vaccines Administered Orally Consumption Volume, Revenue and Growth Rate Forecast (2023-2032)
15.2.4 East Asia Human Vaccines Administered Orally Consumption Volume, Revenue and Growth Rate Forecast (2023-2032)
15.2.5 Europe Human Vaccines Administered Orally Consumption Volume, Revenue and Growth Rate Forecast (2023-2032)
15.2.6 South Asia Human Vaccines Administered Orally Consumption Volume, Revenue and Growth Rate Forecast (2023-2032)
15.2.7 Southeast Asia Human Vaccines Administered Orally Consumption Volume, Revenue and Growth Rate Forecast (2023-2032)
15.2.8 Middle East Human Vaccines Administered Orally Consumption Volume, Revenue and Growth Rate Forecast (2023-2032)
15.2.9 Africa Human Vaccines Administered Orally Consumption Volume, Revenue and Growth Rate Forecast (2023-2032)
15.2.10 Oceania Human Vaccines Administered Orally Consumption Volume, Revenue and Growth Rate Forecast (2023-2032)
15.2.11 South America Human Vaccines Administered Orally Consumption Volume, Revenue and Growth Rate Forecast (2023-2032)
15.3 Global Human Vaccines Administered Orally Consumption Volume, Revenue and Price Forecast by Type (2023-2032)
15.3.1 Global Human Vaccines Administered Orally Consumption Forecast by Type (2023-2032)
15.3.2 Global Human Vaccines Administered Orally Revenue Forecast by Type (2023-2032)
15.3.3 Global Human Vaccines Administered Orally Price Forecast by Type (2023-2032)
15.4 Global Human Vaccines Administered Orally Consumption Volume Forecast by Application (2023-2032)
15.5 Human Vaccines Administered Orally Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
